ClinicalTrials.gg
CompletedNCT01562821Updated Jan 13, 2017

Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

A Phase 2 interventional study of activated recombinant human factor VII and activated recombinant human factor VII in Acquired Bleeding Disorder and Cirrhosis, sponsored by Novo Nordisk A/S. Completed at 7 sites in 3 countries. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-13.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 128 studies in Fibrosis with a site in China — 44 open to participants now, 53 under way, 2 of them phase 3. Fibrosis · China.

Enrollment
20th of 67
235 · median 120
Started
2001
the only one that year
Phase 2
5 of 128
1 open now
Registered
5th of 128
by date

Among the 128 studies in Fibrosis with a site in China, this one is the 20th largest by enrollment of the 67 interventional ones that give a count, is the only one that started in 2001, is one of 5 in phase 2, and was the 5th registered.

Fibrosis

1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.

Browse Fibrosis studies →

Open to participants now

44 of the 128 studies in Fibrosis with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 196 Fibrosis studies recruiting now, 111 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Fibrosis with a site in China, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.

03

Conditions studied

  • Acquired Bleeding Disorder
  • Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cirrhosis (Child-Turcotte Score A, B, or C)
  • Scheduled to undergo partial hepatectomy due to liver cancer or benign tumours

Exclusion criteria

Exclusion Criteria:

  • Portal vein thrombosis
  • Clinically documented DVT (deep venous thrombosis)
  • Clinically documented symptoms of severe cardiovascular disease and/or previous myocardial/pulmonary infarction or stroke
  • Present renal insufficiency requiring dialysis
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    Low dose

    Drug: activated recombinant human factor VII

  • Experimental
    High dose

    Drug: activated recombinant human factor VII

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery

  • An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery

  • Drugplacebo

    An initial placebo bolus dose followed by placebo every second hour until completion of surgery

06

What researchers measure

Primary outcomes

  1. The RBC transfusion requirements

Secondary outcomes

  1. Number of transfusion product units

  2. Change in coagulation-related parameters

  3. Adverse events

07

Study locations

7 sites
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100021, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200438, China
  • Novo Nordisk Investigational Site
    Beijing, China
  • Novo Nordisk Investigational Site
    Taipei, 100, Taiwan
  • Novo Nordisk Investigational Site
    Taipei, 112, Taiwan
  • Novo Nordisk Investigational Site
    Bangkok, 10330, Thailand
  • Novo Nordisk Investigational Site
    Bangkok, 10700, Thailand
08

References and documents

Publications

  • Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, Nivatvongs S, Lee PH. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg. 2006 Feb;191(2):245-9. doi: 10.1016/j.amjsurg.2005.10.019. PubMed 16442954 ↗
  • Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion. 2006 Jun;46(6):919-33. doi: 10.1111/j.1537-2995.2006.00824.x. PubMed 16734808 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2001, a primary completion of Dec 2002 and a completion of Dec 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2012
First posted
Mar 26, 2012
Start
Jul 2001
Primary completionActual
Dec 2002
CompletionActual
Dec 2002
Last update
Jan 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01562821
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 26, 2012
Start date
Jul 2001
Primary completion
Dec 2002
Completion
Dec 2002
Last update
Jan 13, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion